临床淋巴结阳性前列腺癌:哪些患者适合根治性前列腺切除术?淋巴结负荷对长期结局的影响
在三个转诊中心接受根治性前列腺切除术(RP)加淋巴结清扫的162例临床淋巴结阳性前列腺癌患者中,中位随访64个月,8年无临床复发(CR)生存率为59%、无癌特异性死亡生存率为80%。活检分级分组与术前淋巴结负荷可区分获益人群:分级分组1-3且临床淋巴结≤2枚者CR<10%,分级分组4-5且腹膜后淋巴结受累者8年CR达60%。
要点
- 活检分级分组1-3和/或盆腔淋巴结肿大者,多模式治疗中的RP可能有一席之地。
- 分级分组4-5或腹膜后淋巴结受累者肿瘤学结局更差,应考虑 upfront 全身治疗。
- 术前活检分级分组与淋巴结负荷可用于筛选适合局部手术的患者。
核心结论
- 多模式治疗中的手术可能适用于活检分级分组1-3和/或盆腔淋巴结肿大的前列腺癌患者。
- 分级分组4-5及腹膜后淋巴结病变与更差的肿瘤学结局相关。
研究设计与样本
- 多中心回顾性研究,纳入三个转诊中心接受RP加淋巴结清扫的162例临床淋巴结阳性前列腺癌患者。
- 以常规影像发现的转移作为临床复发(CR)定义,采用Kaplan-Meier分析和回归树分析。
主要发现
- 80%患者淋巴结病变仅位于盆腔,20%位于腹膜后±盆腔;阳性淋巴结中位大小13mm。
- 84例(52%)接受新辅助雄激素剥夺治疗,127例(78%)有病理淋巴结侵犯;存活者中位随访64个月。
- 8年无CR生存率59%,无癌特异性死亡生存率80%。
- 活检分级分组1-3且临床淋巴结≤2枚者CR<10%;活检分级分组4-5且腹膜后淋巴结受累者RP后8年CR达60%。
- 回归树判别力按ROC曲线下面积为76%。
关键数值与推荐
- 活检分级分组1-3且临床淋巴结≤2枚:CR<10%。
- 活检分级分组4-5合并腹膜后淋巴结受累:8年CR达60%。
- 8年无CR生存率59%,8年无癌特异性死亡生存率80%。
临床怎么用
- 术前结合活检分级分组与淋巴结分布/负荷筛选RP候选者,盆腔局限且低分级者可考虑局部手术。
- 高分级分组或腹膜后淋巴结受累者优先考虑全身治疗。
局限性
- 可能存在未测量的混杂因素。
- 样本量相对较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting. OBJECTIVE: To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. DESIGN, SETTING, AND PARTICIPANTS: We identified 162 patients with lymphadenopathies treated with RP and lymph node dissection at three referral centers. OUTCOME MEASURES AND STATISTICAL ANALYSES: CR was defined as the onset of metastases detected by conventional imaging. Kaplan-Maier analyses assessed time to CR after stratifying patients according to the site of lymphadenopathies and nodal burden. Regression tree analysis stratified patients into risk groups on the basis of their preoperative characteristics. RESULTS AND LIMITATIONS: Overall, 80% of patients had lymphadenopathies in the pelvis alone and 20% in the retroperitoneum±pelvis. The median size of positive nodes was 13mm. A total of 84 patients (52%) received neoadjuvant androgen deprivation therapy and 127 (78%) had pathological lymph node invasion. The median follow-up for survivors was 64 mo. The 8-yr CR-free and CSM-free survival rates were 59% and 80%, respectively. Biopsy grade group and preoperative nodal burden should identify patients more likely to experience CR. While <10% of men with biopsy grade group 1-3 and two or fewer clinical lymphadenopathies developed CR, up to 60% of patients with biopsy grade group 4-5 and retroperitoneal node involvement ultimately experienced CR at 8 yr after RP. The discrimination of the regression tree was 76% according to the area under the receiver operating characteristic curve. Our study is limited by potential unmeasured confounders and the relatively small sample size. CONCLUSIONS: Surgery in a multimodal setting might play a role in PCa patients with biopsy grade group 1-3 and/or enlarged nodes in the pelvis. Conversely, grade group 4-5 PCa and lymphadenopathies in the retroperitoneum are associated with worse oncologic outcomes. PATIENT SUMMARY: Approximately half of prostate cancer patients with clinical lymphadenopathies treated with radical prostatectomy are free from metastases at 8-yr follow-up. Radical prostatectomy with or without systemic therapies might play a role in selected patients with biopsy grade group 1-3 disease and/or enlarged nodes in the pelvis. Conversely, a higher grade group and the presence of lymphadenopathies in the retroperitoneum should identify candidates for systemic therapies upfront.
引用
- Gandaglia G, Soligo M, Battaglia A, et al. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. Eur Urol. 2018. PMID: 30409676. doi:10.1016/j.eururo.2018.10.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。